Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study

Introduction: The prevalence of menopausal women with confirmed vulvovaginal atrophy (VVA) oscillates between 67e98%. Aim: To assess the prevalence of postmenopausal women with VVA confirmed by gynecologic clinical assessment among all women attending menopause centers in Spain, as well as to descri...

Descripción completa

Detalles Bibliográficos
Autores: Palacios Ruiz, Lucas Santiago, González, Silvia P., Fernández-Abellán, Micaela, Manubens, Montserrat, García-Alfaro, Pascual, Castelo-Branco Flores, Camil
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/141164
Acceso en línea:https://hdl.handle.net/2445/141164
Access Level:acceso abierto
Palabra clave:Menopausa
Malalties de l'aparell genital femení
Malalties de la vagina
Malalties de la vulva
Menopause
Female reproductive system diseases
Vagina diseases
Vulva diseases
id ES_0679d13bfc2d9165dcd41a7b9eb4be44
oai_identifier_str oai:diposit.ub.edu:2445/141164
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES StudyPalacios Ruiz, Lucas SantiagoGonzález, Silvia P.Fernández-Abellán, MicaelaManubens, MontserratGarcía-Alfaro, PascualCastelo-Branco Flores, CamilMenopausaMalalties de l'aparell genital femeníMalalties de la vaginaMalalties de la vulvaMenopauseFemale reproductive system diseasesVagina diseasesVulva diseasesIntroduction: The prevalence of menopausal women with confirmed vulvovaginal atrophy (VVA) oscillates between 67e98%. Aim: To assess the prevalence of postmenopausal women with VVA confirmed by gynecologic clinical assessment among all women attending menopause centers in Spain, as well as to describe the impact of VVA on quality of life and sexual functioning. Methods: Women aged 45e75 years old with the last menstrual period >12 months before were included in a cross-sectional study. Main Outcome Measures: Women with 1 VVA symptoms filled out a number of questionnaires, including EuroQoL, Day-to-Day Impact of Vaginal Aging, Female Sexual Function Index, and Female Sexual Distress Scale-revised. A gynecologic examination was performed to confirm diagnosis. Results: 1,177 evaluable patients were included. VVA was confirmed in 87.3% of the patients. Almost 80% of women who acknowledged being sexually active (n ¼ 717) presented pain during intercourse. As compared with patients without confirmed VVA (n ¼ 66), patients with confirmed VVA (n ¼ 1,028) were significantly older (P < .0001), had lower rates of sexual activity (P < .05), and used more VVA treatments (P < .05). Severe vaginal atrophy and severe vulvar atrophy were more prevalent in VVA-confirmed women (P < .0001, in both cases). No differences regarding the confirmation of VVA were observed for EuroQoL andDay-to-Day Impact of Vaginal Aging quality-oflife questionnaires. Sexual function measured through the Female Sexual Function Index score was significantly reduced in sexually-active patients with confirmed VVA (P < .05). Conclusion: VVA signs and symptoms are highly prevalent in Spanish postmenopausal women. Confirmation of VVA diagnosis was associated with impaired sexual function. The early recognition of VVA symptoms should be actively promoted in medical practice, instead of waiting until signs appear to exclude other reasons for VVA and to manage treatment effectively.2019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/141164Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.esxm.2019.01.005Sexual Medicine, 2019, vol. 7, p. 207-216https://doi.org/10.1016/j.esxm.2019.01.005cc-by-nc-nd (c) Palacios, Santiago et al., 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1411642026-05-27T06:46:51Z
dc.title.none.fl_str_mv Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
title Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
spellingShingle Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
Palacios Ruiz, Lucas Santiago
Menopausa
Malalties de l'aparell genital femení
Malalties de la vagina
Malalties de la vulva
Menopause
Female reproductive system diseases
Vagina diseases
Vulva diseases
title_short Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
title_full Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
title_fullStr Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
title_full_unstemmed Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
title_sort Impact of vulvovaginal atrophy of menopause in Spanish women: prevalence and symptoms according to the EVES Study
dc.creator.none.fl_str_mv Palacios Ruiz, Lucas Santiago
González, Silvia P.
Fernández-Abellán, Micaela
Manubens, Montserrat
García-Alfaro, Pascual
Castelo-Branco Flores, Camil
author Palacios Ruiz, Lucas Santiago
author_facet Palacios Ruiz, Lucas Santiago
González, Silvia P.
Fernández-Abellán, Micaela
Manubens, Montserrat
García-Alfaro, Pascual
Castelo-Branco Flores, Camil
author_role author
author2 González, Silvia P.
Fernández-Abellán, Micaela
Manubens, Montserrat
García-Alfaro, Pascual
Castelo-Branco Flores, Camil
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Menopausa
Malalties de l'aparell genital femení
Malalties de la vagina
Malalties de la vulva
Menopause
Female reproductive system diseases
Vagina diseases
Vulva diseases
topic Menopausa
Malalties de l'aparell genital femení
Malalties de la vagina
Malalties de la vulva
Menopause
Female reproductive system diseases
Vagina diseases
Vulva diseases
description Introduction: The prevalence of menopausal women with confirmed vulvovaginal atrophy (VVA) oscillates between 67e98%. Aim: To assess the prevalence of postmenopausal women with VVA confirmed by gynecologic clinical assessment among all women attending menopause centers in Spain, as well as to describe the impact of VVA on quality of life and sexual functioning. Methods: Women aged 45e75 years old with the last menstrual period >12 months before were included in a cross-sectional study. Main Outcome Measures: Women with 1 VVA symptoms filled out a number of questionnaires, including EuroQoL, Day-to-Day Impact of Vaginal Aging, Female Sexual Function Index, and Female Sexual Distress Scale-revised. A gynecologic examination was performed to confirm diagnosis. Results: 1,177 evaluable patients were included. VVA was confirmed in 87.3% of the patients. Almost 80% of women who acknowledged being sexually active (n ¼ 717) presented pain during intercourse. As compared with patients without confirmed VVA (n ¼ 66), patients with confirmed VVA (n ¼ 1,028) were significantly older (P < .0001), had lower rates of sexual activity (P < .05), and used more VVA treatments (P < .05). Severe vaginal atrophy and severe vulvar atrophy were more prevalent in VVA-confirmed women (P < .0001, in both cases). No differences regarding the confirmation of VVA were observed for EuroQoL andDay-to-Day Impact of Vaginal Aging quality-oflife questionnaires. Sexual function measured through the Female Sexual Function Index score was significantly reduced in sexually-active patients with confirmed VVA (P < .05). Conclusion: VVA signs and symptoms are highly prevalent in Spanish postmenopausal women. Confirmation of VVA diagnosis was associated with impaired sexual function. The early recognition of VVA symptoms should be actively promoted in medical practice, instead of waiting until signs appear to exclude other reasons for VVA and to manage treatment effectively.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/141164
url https://hdl.handle.net/2445/141164
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.esxm.2019.01.005
Sexual Medicine, 2019, vol. 7, p. 207-216
https://doi.org/10.1016/j.esxm.2019.01.005
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Palacios, Santiago et al., 2019
http://creativecommons.org/licenses/by-nc-nd/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Palacios, Santiago et al., 2019
http://creativecommons.org/licenses/by-nc-nd/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402920238186496
score 15,301603

Similares en LA Referencia